Tyra Biosciences logo

Tyra Biosciences

TYRA | NASDAQ
Chart Builder DCF Calculator
$19.74
-$0.29 (-1.42%)
At close: Nov 16, 2026, 4:00 PM ET
$19.74
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.42%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
26.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #883/1021 (Top 86%)

Key Statistics

Market Data

Market Cap $1.36B
1D Range
19.60 20.61
52W Range
15.90 39.61

Valuation (TTM)

PE -7.48
PB 1.97
EV/EBITDA -3.85

Valuation (NTM)

Forward PE N/A
Forward PEG -0.18
Price Target $42.00
Loading financial charts...

Profile

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, ...

Sector Healthcare
Industry Biotechnology
Employees 87
IPO Date Sep 15, 2021
Fiscal Year January - December

Latest News

Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights

6 days ago · prnewswire.com

Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences to Participate in Upcoming Investor Conferences

11 days ago · prnewswire.com

Tyra Biosciences to Participate in Upcoming Investor Conferences
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

1 month ago · zacks.com

Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

2 months ago · prnewswire.com

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript

2 months ago · seekingalpha.com

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
Why Is Tyra Biosciences Stock Sinking Wednesday?

2 months ago · benzinga.com

Why Is Tyra Biosciences Stock Sinking Wednesday?
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results

2 months ago · investors.com

Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

2 months ago · barrons.com

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

3 months ago · prnewswire.com

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

6 months ago · prnewswire.com

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$42.00
Upside
+112.77%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.